Proteus™ is Chosen by Leading Edge Research Center for Proteomics Research
News Apr 26, 2006
GenoLogics Life Sciences Software Inc. has announced that Fred Hutchinson Cancer Research Center chose Proteus™, GenoLogics’ proteomics purposed lab and data management solution, to use in its cancer biomarker discovery research in early detection of ovarian cancer.
GenoLogics worked with the Hutchinson Center to integrate Proteus with the Center’s recently released Computational Proteomics Analysis System (CPAS) data repository.
Proteus will be used in the lab of Dr. Martin McIntosh, associate member of the Public Health Sciences Division at the Hutchinson Center and principal investigator of the Center’s Computational Proteomics Laboratory (CPL).
The CPL develops and uses computational approaches for protein and proteomics research.
"We were looking for a scientific data management solution based on open standards that could help us share and disseminate data with other leading cancer centers around the world in an eXperiment ARchive format (XAR)," McIntosh commented. "GenoLogics’ Proteus met these requirements."
GenoLogics claims that, Proteus is the only data management solution that can export a complete proteomics experiment XAR data file, based on the FuGE (Functional Genomics Experiment) object model with proteomics extensions, and import the file into the lab’s open source Computational Proteomics and Analysis System (CPAS) data repository.
CPAS is used to manage the CPL containing over 75 million putative MS2 peptides, growing at 1 million per week. The National Cancer Institute and the Canary Foundation funded the development of CPAS.
Several cancer research institutes nationally and internationally have joined with the Hutchinson Center to form an International Cancer Biomarker Consortium (ICBC) with a goal to improve discovery methods and identify biomarkers.
Michael Ball, CEO of GenoLogics stated, "We believe the ICBC is an important initiative and we fully support the goals of this consortium."
"GenoLogics is a founding member of the ICBC Informatics Working Group and we look forward to working with the Hutchinson Center and ICBC to advance early detection cancer research."
Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosisREAD MORE